New Alzheimer's drug sparks backlash over FDA, pricing | The Hill: Healthcare Policy

admin June 12, 2021

The approval of a new Alzheimer's drug has sparked a fierce backlash amid concerns about both price and its effectiveness.The Biogen drug, marketed under the name Aduhelm, is the first Alzheimer's treatment approved in nearly 20 years.Yet it comes...